About
Our Science
News
Contact Us
About
Our Science
News
Contact Us
News & Resources
MEDIA COVERAGE
Press Releases
Articles
PRESENTATIONS
Events
View All
Events
Nov 16, 2022 |
Join ProJenX at the 2022 International Symposium on ALS/MND
Read More
Presentations
Nov 16, 2022 |
Safety and pharmacokinetics of prosetin, a novel, brain penetrant MAP4K inhibitor in development for the treatment of ALS
Read More
Media Coverage
Nov 16, 2022 | GEN: Genetic Engineering and Biotechnology News
Stress Test: ProJenX’s Oral Drug Shows Early Promise vs. ALS
Read More
Media Coverage
Nov 2, 2022 | BioCentury
ProJenX: Protecting Neurons to Treat ALS
Read More
Media Coverage
Sep 6, 2022 | BioSpace
ALS Thought Leaders Weigh in Ahead of Second Amylyx Adcomm
Read More
Press Release
May 18, 2022 | ProJenX
ProJenX Names Life Sciences Industry Veteran Stan E. Abel as CEO
Read More
Media Coverage
Mar 11, 2022 | ALS News Today
Dosing Begins in Phase 1 Trial of Prosetin
Read More
Press Release
Mar 1, 2022 | ProJenX
ProJenX Announces First Person Dosed in Phase 1 Study of Prosetin
Read More
Press Release
Feb 16, 2022 | ProJenX
ProJenX Launches to Advance Novel, Targeted Therapies for ALS and Other Brain Diseases
Read More
Article
Nov 16, 2019 | Cell Press
Development of MAP4 Kinase Inhibitors as Motor Neuron-Protecting Agents
Read More
Article
Jan 16, 2019 | The American Society of Gene and Cell Therapy
A Stem Cell-Based Screening Platform Identifies Compounds…
Read More
Contact Us to Learn More About Our Fight Against ALS
Contact Us
